Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cinryze "complete response" letter means HAE race is still on

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA's "complete response" letter to ViroPharma regarding its supplemental Cinryze filing for treatment of acute attacks of hereditary angioedema requests an additional clinical trial, stalling the firm's progress in a race with two other C1 esterase inhibitors to be the first acute HAE treatment approved in the U.S. ViroPharma said June 4 that FDA believes the placebo-controlled trial submitted in support of the sBLA "lacked robustness." Cinryze, which was first to market with a prophylaxis claim, is now in the same boat as CSL Behring's C1 esterase inhibitor Berinert: CSL received a "complete response" letter Dec. 5, 2008 requesting another trial. A filing for the third C1 candidate, Pharming's Rhucin, is expected in September. Pharming said March 31 that it is conducting additional data analyses at FDA's behest

You may also be interested in...

Woodcock Faces Maze Of Rules To Become Commissioner Nominee

Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.

Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.

Medicare Part D Protected Classes Targeted in Last-Minute Payment Demo Update

If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts